Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.55
BIIB's Cash to Debt is ranked lower than
60% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 56.57 vs. BIIB: 0.55 )
Ranked among companies with meaningful Cash to Debt only.
BIIB' s Cash to Debt Range Over the Past 10 Years
Min: 0.25  Med: 1.49 Max: N/A
Current: 0.55
Equity to Asset 0.50
BIIB's Equity to Asset is ranked lower than
68% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. BIIB: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
BIIB' s Equity to Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.75 Max: 0.84
Current: 0.5
0.48
0.84
Interest Coverage 33.87
BIIB's Interest Coverage is ranked lower than
58% of the 364 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BIIB: 33.87 )
Ranked among companies with meaningful Interest Coverage only.
BIIB' s Interest Coverage Range Over the Past 10 Years
Min: 19.25  Med: 51.03 Max: 505.19
Current: 33.87
19.25
505.19
F-Score: 5
Z-Score: 6.09
M-Score: -3.02
WACC vs ROIC
5.60%
33.47%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 47.11
BIIB's Operating margin (%) is ranked higher than
98% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -76.21 vs. BIIB: 47.11 )
Ranked among companies with meaningful Operating margin (%) only.
BIIB' s Operating margin (%) Range Over the Past 10 Years
Min: 16.4  Med: 31.63 Max: 45.44
Current: 47.11
16.4
45.44
Net-margin (%) 33.79
BIIB's Net-margin (%) is ranked higher than
96% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. BIIB: 33.79 )
Ranked among companies with meaningful Net-margin (%) only.
BIIB' s Net-margin (%) Range Over the Past 10 Years
Min: 8.11  Med: 23.31 Max: 32.95
Current: 33.79
8.11
32.95
ROE (%) 33.90
BIIB's ROE (%) is ranked higher than
95% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -31.69 vs. BIIB: 33.90 )
Ranked among companies with meaningful ROE (%) only.
BIIB' s ROE (%) Range Over the Past 10 Years
Min: 3.09  Med: 18.97 Max: 35.15
Current: 33.9
3.09
35.15
ROA (%) 19.89
BIIB's ROA (%) is ranked higher than
94% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -26.89 vs. BIIB: 19.89 )
Ranked among companies with meaningful ROA (%) only.
BIIB' s ROA (%) Range Over the Past 10 Years
Min: 2.57  Med: 13.24 Max: 22.42
Current: 19.89
2.57
22.42
ROC (Joel Greenblatt) (%) 180.35
BIIB's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 898 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. BIIB: 180.35 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIIB' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 34.4  Med: 77.96 Max: 189.7
Current: 180.35
34.4
189.7
Revenue Growth (3Y)(%) 26.50
BIIB's Revenue Growth (3Y)(%) is ranked higher than
87% of the 489 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. BIIB: 26.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BIIB' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.5  Med: 24.80 Max: 78.2
Current: 26.5
-2.5
78.2
EBITDA Growth (3Y)(%) 35.90
BIIB's EBITDA Growth (3Y)(%) is ranked higher than
86% of the 489 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. BIIB: 35.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BIIB' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -16.3  Med: 31.80 Max: 79
Current: 35.9
-16.3
79
EPS Growth (3Y)(%) 38.70
BIIB's EPS Growth (3Y)(%) is ranked higher than
85% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. BIIB: 38.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BIIB' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -65.5  Med: 38.70 Max: 201.1
Current: 38.7
-65.5
201.1
» BIIB's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

BIIB Guru Trades in Q2 2015

Andreas Halvorsen 513,444 sh (New)
Vanguard Health Care Fund 1,780,330 sh (+425.02%)
Richard Snow 10,500 sh (+320.00%)
Jim Simons 105,261 sh (+247.40%)
RS Investment Management 29,507 sh (+8.49%)
Ron Baron 9,144 sh (unchged)
Stanley Druckenmiller Sold Out
John Burbank Sold Out
Ray Dalio Sold Out
Steven Cohen Sold Out
Ken Fisher 80,932 sh (-0.16%)
PRIMECAP Management 16,501,541 sh (-0.35%)
Pioneer Investments 18,360 sh (-0.61%)
Murray Stahl 8,333 sh (-1.36%)
Mairs and Power 1,095 sh (-2.23%)
Mario Gabelli 4,797 sh (-2.74%)
Frank Sands 4,732,945 sh (-5.52%)
Jeremy Grantham 251,045 sh (-62.48%)
Paul Tudor Jones 600 sh (-87.70%)
» More
Q3 2015

BIIB Guru Trades in Q3 2015

Ray Dalio 14,766 sh (New)
John Burbank 10,551 sh (New)
Joel Greenblatt 9,410 sh (New)
Steven Cohen 6,800 sh (New)
Richard Snow 45,861 sh (+336.77%)
Vanguard Health Care Fund 3,666,723 sh (+105.96%)
Signature Select Canadian Fund 7,900 sh (+43.64%)
Ken Fisher 112,448 sh (+38.94%)
Ron Baron 11,814 sh (+29.20%)
Mairs and Power 1,095 sh (unchged)
Mario Gabelli 4,797 sh (unchged)
Andreas Halvorsen Sold Out
RS Investment Management Sold Out
Paul Tudor Jones Sold Out
Pioneer Investments Sold Out
PRIMECAP Management 15,843,460 sh (-3.99%)
Murray Stahl 7,713 sh (-7.44%)
Frank Sands 4,121,400 sh (-12.92%)
Jeremy Grantham 179,221 sh (-28.61%)
Jim Simons 34,961 sh (-66.79%)
» More
Q4 2015

BIIB Guru Trades in Q4 2015

First Eagle Investment 193,885 sh (New)
John Buckingham 17,389 sh (New)
Jeff Auxier 7,195 sh (New)
Andreas Halvorsen 368,864 sh (New)
Paul Tudor Jones 4,368 sh (New)
John Paulson 36,200 sh (New)
Steven Cohen 86,700 sh (+1175.00%)
Joel Greenblatt 84,577 sh (+798.80%)
Ray Dalio 25,106 sh (+70.03%)
Vanguard Health Care Fund 3,810,023 sh (+3.91%)
Mario Gabelli 4,805 sh (+0.17%)
Mairs and Power 1,095 sh (unchged)
Samuel Isaly 200,000 sh (unchged)
Jim Simons Sold Out
John Burbank Sold Out
Murray Stahl 7,705 sh (-0.10%)
PRIMECAP Management 15,810,625 sh (-0.21%)
Ken Fisher 110,475 sh (-1.75%)
Richard Snow 40,290 sh (-12.15%)
Ron Baron 10,240 sh (-13.32%)
Frank Sands 3,367,531 sh (-18.29%)
Jeremy Grantham 98,334 sh (-45.13%)
» More
Q1 2016

BIIB Guru Trades in Q1 2016

Pioneer Investments 880 sh (New)
Ronald Muhlenkamp 23,853 sh (New)
Jim Simons 127,661 sh (New)
Lee Ainslie 9,370 sh (New)
Joel Greenblatt 298,673 sh (+253.14%)
John Paulson 118,400 sh (+227.07%)
Richard Snow 91,801 sh (+127.85%)
Ron Baron 16,047 sh (+56.71%)
Jeff Auxier 9,015 sh (+25.30%)
Steven Cohen 102,200 sh (+17.88%)
First Eagle Investment 224,585 sh (+15.83%)
PRIMECAP Management 16,246,726 sh (+2.76%)
Mario Gabelli 4,810 sh (+0.10%)
Murray Stahl 7,705 sh (unchged)
Vanguard Health Care Fund 3,810,023 sh (unchged)
Ronald Muhlenkamp 3,000 sh (unchged)
Samuel Isaly 200,000 sh (unchged)
John Buckingham 16,809 sh (-3.34%)
Mairs and Power 1,025 sh (-6.39%)
Frank Sands 3,141,109 sh (-6.72%)
Ray Dalio 23,106 sh (-7.97%)
Ken Fisher 90,405 sh (-18.17%)
Andreas Halvorsen 230,947 sh (-37.39%)
Paul Tudor Jones 1,000 sh (-77.11%)
Jeremy Grantham 1,380 sh (-98.60%)
» More
» Details

Insider Trades

Latest Guru Trades with BIIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:AMGN, NAS:GILD, NAS:CELG » details
Traded in other countries:BIIB34.Brazil, IDP.Germany, BIIB.Mexico, BIIB.Switzerland, 0R1B.UK,
Biogen Idec Inc, is a biopharmaceutical company. The Company discovers, develops, manufactures and markets therapies for neurological, autoimmune and hematologic disorders.

Biogen Idec Inc was formed as a California corporation in 1985 and became a Delaware corporation in 1985. The Company is a biotechnology company. It discovers, develops, manufactures and markets therapies for the treatment of autoimmune disorders, neurodegenerative diseases and hemophilia. It also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions. The Company's marketed products include MA Products, AVONEX; TYSABRI; RITUXAN; FAMPYRA; FUMADERM. The Company develop, manufacture and market a number of products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, to a loss of muscle control, paralysis and, in some cases, death. AVONEX is one of the prescribed treatments for relapsing forms of MS. TYSABRI has advanced the treatment of relapsing MS with its established efficacy. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and also approved in the U.S. to treat Crohn's disease, an inflammatory disease of the intestines. RITUXAN is a prescribed monoclonal antibody therapeutic used to treat non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and two forms of ANCA-associated vasculitis. FAMPYRA is the first treatment that addresses the unmet medical need of walking improvement in adult patients with MS who have walking disability. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. The Company is facing competition from other biotechnology firms and large pharmaceutical companies. The Company is subject to various federal and state laws pertaining to health care fraud and abuse, including anti-kickback laws and false claims laws.

Top Ranked Articles about Biogen Inc

Richard Snow Boosts Biogen, Keysight Technologies The largest increases by the guru during the 1st quarter
Richard Snow (Trades, Portfolio) is founder of Snow Capital. Snow began his career investing the proceeds from the sale of the Snow family businesses. During the first quarter he bought the following shares: Read more...
10 Years of Strong Returns: Priceline, Biogen Companies with high profitability and strong returns
According to GuruFocus' All-in-One Screener, the following stocks have had strong performances over the last 10 years with high and steady returns as well as profitability. EPS has also grown steadily with the companies' revenues. Most of these companies have great cash-to-debt ratios. Read more...
Jeff Auxier Takes Plunge in Fastenal, a Stock From Watchlist Despite its continually high price, Auxier purchased a small holding in nuts and bolts maker
Jeff Auxier (Trades, Portfolio) of Auxier Asset Management picked up eight new holdings during the fourth quarter, including Fastenal (NASDAQ:FAST), an industrial stock Auxier believed to be too richly valued this past August. Read more...
Jean Hynes Finds Her Pot of Gold In the 3rd quarter, Vanguard Health Care Fund doubled stake in Biogen
The Vanguard Health Care Fund doubled its stake in Biogen Inc. (NASDAQ:BIIB), one of the world’s leading biotechnology companies, in the third quarter. Read more...
Vanguard Raises Stakes in Biogen, Mylan, Merck Fund buys no new stakes in 3rd quarter
As its name suggests, Vanguard Health Care Fund (Trades, Portfolio) is almost exclusively interested in health care companies. It bought no new stakes in the third quarter, but it did make additions to several existing stakes. Read more...
Biogen Among Murray Stahl's Holdings With Growing Earnings The biotechnology company's EPS has grown 28% over past five years
Murray Stahl (Trades, Portfolio) is the chairman of Horizon Asset Management Inc. He is also director of Research and co-portfolio manager of the Small Cap Opportunities Fund and the Paradigm Fund. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 17.76
BIIB's P/E(ttm) is ranked lower than
60% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 30.30 vs. BIIB: 17.76 )
Ranked among companies with meaningful P/E(ttm) only.
BIIB' s P/E(ttm) Range Over the Past 10 Years
Min: 11.74  Med: 26.84 Max: 467.75
Current: 17.76
11.74
467.75
Forward P/E 13.97
BIIB's Forward P/E is ranked higher than
66% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 19.05 vs. BIIB: 13.97 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 17.76
BIIB's PE(NRI) is ranked lower than
60% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.30 vs. BIIB: 17.76 )
Ranked among companies with meaningful PE(NRI) only.
BIIB' s PE(NRI) Range Over the Past 10 Years
Min: 11.73  Med: 26.83 Max: 530.11
Current: 17.76
11.73
530.11
Price/Owner Earnings (ttm) 23.19
BIIB's Price/Owner Earnings (ttm) is ranked lower than
59% of the 132 Companies
in the Global Biotechnology industry.

( Industry Median: 34.28 vs. BIIB: 23.19 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BIIB' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.81  Med: 27.58 Max: 168.8
Current: 23.19
10.81
168.8
P/B 6.16
BIIB's P/B is ranked lower than
63% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 3.51 vs. BIIB: 6.16 )
Ranked among companies with meaningful P/B only.
BIIB' s P/B Range Over the Past 10 Years
Min: 1.71  Med: 3.77 Max: 9.6
Current: 6.16
1.71
9.6
P/S 6.08
BIIB's P/S is ranked lower than
66% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 11.92 vs. BIIB: 6.08 )
Ranked among companies with meaningful P/S only.
BIIB' s P/S Range Over the Past 10 Years
Min: 2.81  Med: 6.04 Max: 11.94
Current: 6.08
2.81
11.94
PFCF 20.31
BIIB's PFCF is ranked lower than
55% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 28.09 vs. BIIB: 20.31 )
Ranked among companies with meaningful PFCF only.
BIIB' s PFCF Range Over the Past 10 Years
Min: 10.16  Med: 21.92 Max: 39.29
Current: 20.31
10.16
39.29
POCF 16.84
BIIB's POCF is ranked lower than
58% of the 192 Companies
in the Global Biotechnology industry.

( Industry Median: 23.05 vs. BIIB: 16.84 )
Ranked among companies with meaningful POCF only.
BIIB' s POCF Range Over the Past 10 Years
Min: 7.95  Med: 18.00 Max: 35.29
Current: 16.84
7.95
35.29
EV-to-EBIT 12.92
BIIB's EV-to-EBIT is ranked lower than
55% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 24.11 vs. BIIB: 12.92 )
Ranked among companies with meaningful EV-to-EBIT only.
BIIB' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.1  Med: 18.95 Max: 68.3
Current: 12.92
8.1
68.3
EV-to-EBITDA 11.55
BIIB's EV-to-EBITDA is ranked lower than
59% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 21.11 vs. BIIB: 11.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.6  Med: 15.10 Max: 27
Current: 11.55
6.6
27
PEG 0.57
BIIB's PEG is ranked higher than
65% of the 92 Companies
in the Global Biotechnology industry.

( Industry Median: 2.27 vs. BIIB: 0.57 )
Ranked among companies with meaningful PEG only.
BIIB' s PEG Range Over the Past 10 Years
Min: 0.34  Med: 1.10 Max: 48.49
Current: 0.57
0.34
48.49
Shiller P/E 44.43
BIIB's Shiller P/E is ranked lower than
99.99% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 57.65 vs. BIIB: 44.43 )
Ranked among companies with meaningful Shiller P/E only.
BIIB' s Shiller P/E Range Over the Past 10 Years
Min: 35.83  Med: 73.77 Max: 119.73
Current: 44.43
35.83
119.73
Current Ratio 2.59
BIIB's Current Ratio is ranked higher than
67% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. BIIB: 2.59 )
Ranked among companies with meaningful Current Ratio only.
BIIB' s Current Ratio Range Over the Past 10 Years
Min: 0.78  Med: 3.32 Max: 17.39
Current: 2.59
0.78
17.39
Quick Ratio 2.25
BIIB's Quick Ratio is ranked higher than
70% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. BIIB: 2.25 )
Ranked among companies with meaningful Quick Ratio only.
BIIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 2.90 Max: 16.79
Current: 2.25
0.7
16.79
Days Inventory 262.83
BIIB's Days Inventory is ranked lower than
99.99% of the 446 Companies
in the Global Biotechnology industry.

( Industry Median: 128.00 vs. BIIB: 262.83 )
Ranked among companies with meaningful Days Inventory only.
BIIB' s Days Inventory Range Over the Past 10 Years
Min: 219.47  Med: 238.11 Max: 266.3
Current: 262.83
219.47
266.3
Days Sales Outstanding 46.56
BIIB's Days Sales Outstanding is ranked higher than
75% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. BIIB: 46.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.79  Med: 44.30 Max: 48.61
Current: 46.56
39.79
48.61
Days Payable 79.80
BIIB's Days Payable is ranked lower than
58% of the 442 Companies
in the Global Biotechnology industry.

( Industry Median: 60.55 vs. BIIB: 79.80 )
Ranked among companies with meaningful Days Payable only.
BIIB' s Days Payable Range Over the Past 10 Years
Min: 71.44  Med: 105.99 Max: 148.21
Current: 79.8
71.44
148.21

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 18.68
BIIB's Price/Tangible Book is ranked lower than
74% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. BIIB: 18.68 )
Ranked among companies with meaningful Price/Tangible Book only.
BIIB' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.91  Med: 6.15 Max: 26.49
Current: 18.68
0.91
26.49
Price/Projected FCF 1.97
BIIB's Price/Projected FCF is ranked lower than
66% of the 178 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. BIIB: 1.97 )
Ranked among companies with meaningful Price/Projected FCF only.
BIIB' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.65  Med: 2.13 Max: 25.99
Current: 1.97
0.65
25.99
Price/DCF (Earnings Based) 0.63
BIIB's Price/DCF (Earnings Based) is ranked lower than
59% of the 17 Companies
in the Global Biotechnology industry.

( Industry Median: 1.31 vs. BIIB: 0.63 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.01
BIIB's Price/Median PS Value is ranked higher than
63% of the 679 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. BIIB: 1.01 )
Ranked among companies with meaningful Price/Median PS Value only.
BIIB' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 0.99 Max: 15.72
Current: 1.01
0.23
15.72
Price/Peter Lynch Fair Value 0.71
BIIB's Price/Peter Lynch Fair Value is ranked higher than
66% of the 59 Companies
in the Global Biotechnology industry.

( Industry Median: 1.65 vs. BIIB: 0.71 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BIIB' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.44  Med: 1.41 Max: 20.5
Current: 0.71
0.44
20.5
Price/Graham Number 3.84
BIIB's Price/Graham Number is ranked lower than
99.99% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 3.28 vs. BIIB: 3.84 )
Ranked among companies with meaningful Price/Graham Number only.
BIIB' s Price/Graham Number Range Over the Past 10 Years
Min: 0.5  Med: 3.08 Max: 21.42
Current: 3.84
0.5
21.42
Earnings Yield (Greenblatt) (%) 7.73
BIIB's Earnings Yield (Greenblatt) (%) is ranked higher than
86% of the 1024 Companies
in the Global Biotechnology industry.

( Industry Median: -9.20 vs. BIIB: 7.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIIB' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.5  Med: 5.30 Max: 12.3
Current: 7.73
1.5
12.3
Forward Rate of Return (Yacktman) (%) 32.94
BIIB's Forward Rate of Return (Yacktman) (%) is ranked higher than
72% of the 113 Companies
in the Global Biotechnology industry.

( Industry Median: 14.03 vs. BIIB: 32.94 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BIIB' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -4.6  Med: 25.10 Max: 45.3
Current: 32.94
-4.6
45.3

More Statistics

Revenue (TTM) (Mil) $10,936
EPS (TTM) $ 16.28
Beta0.53
Short Percentage of Float1.03%
52-Week Range $242.07 - 420.99
Shares Outstanding (Mil)219.05

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 11,386 12,208 13,013
EPS ($) 18.28 20.25 22.30
EPS without NRI ($) 18.28 20.25 22.30
EPS Growth Rate
(3Y to 5Y Estimate)
14.96%
» More Articles for BIIB

Headlines

Articles On GuruFocus.com
Jeff Auxier's Spring 2016 Market Commentary May 20 2016 
Richard Snow Boosts Biogen, Keysight Technologies May 12 2016 
10 Years of Strong Returns: Priceline, Biogen Apr 26 2016 
Alaska Air, Delta and NVR Make the 30-30 Club Apr 15 2016 
Undervalued Stocks With Wide Margin of Safety Apr 14 2016 
John Buckingham Trades in ETFs in 4th Quarter Mar 15 2016 
Widely Undervalued Stocks Trading Below Peter Lynch Value Feb 22 2016 
John Paulson Bulks Up Health Care Bet Feb 17 2016 
Jeff Auxier Takes Plunge in Fastenal, a Stock From Watchlist Feb 10 2016 
Jean Hynes Finds Her Pot of Gold Jan 07 2016 

More From Other Websites
How to Discover the Best Biotechs in the World May 31 2016
Biogen Gets Favorable View For TYSABRI Use In Highly Active RRMS May 31 2016
FDA Approves Biogen and AbbVie's MS Treatment May 31 2016
Biogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients... May 31 2016
Biogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients... May 31 2016
12:30 am Biogen receives EU approval for FLIXABI May 30 2016
Biogen & AbbVie's Multiple Sclerosis Drug Gets FDA Nod May 30 2016
FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union May 30 2016
FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union May 30 2016
[$$] Once-Monthly MS Injection Approved in U.S. May 27 2016
Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple... May 27 2016
Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (daclizumab) for Multiple... May 27 2016
Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple... May 27 2016
Biogen, AbbVie once-monthly MS injection wins U.S. approval May 27 2016
Biogen, AbbVie once-monthly MS injection wins U.S. FDA approval May 27 2016
Roche/Biogen Drug Gazyva Beats Rituxan In Cancer Trial May 27 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into... May 27 2016
Biogen (BIIB) Stock is the 'Chart of the Day' May 27 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. -... May 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)